SUMMARY The hemodynamic, cardiovascular, and metabolic effects of acute (intravenous) and prolonged (four weeks oral) timolol treatment were assessed in 16 patients with mild or moderate essential hypertension. Fifteen patients completed the outpatient study and ten showed a fall in mean arterial pressure of at least 10 mm Hg. They also demonstrated a significant fall in supine systolic (7%), diastolic (9%), and mean arterial pressure. Hemodynamic evaluation was performed in 13 patients and cardiac index was found to be reduced with both intravenous (20%) and oral timolol (13%). There was no correlation between the decrease in cardiac index and arterial pressure. Calculated total peripheral resistance rose with intra-TIMOLOL MALEATE is a beta-adrenoreceptor blocking drug which has neither cardioselective nor intrinsic sympathomimetic properties, and it has no membrane stabilizing activity. It has an antihypertensive effect in man1-7 which is comparable to other beta-blocking agents.'
TIMOLOL MALEATE is a beta-adrenoreceptor blocking drug which has neither cardioselective nor intrinsic sympathomimetic properties, and it has no membrane stabilizing activity. It has an antihypertensive effect in man1-7 which is comparable to other beta-blocking agents. ' Initial reports of its hemodynamic effects in patients with hypertension suggested an initial reduction in cardiac index which was not sustained during long-term therapy despite a maintained reduction in arterial pressure.2' 8 Thus, it appeared that total peripheral resistance fell during therapy, a finding not observed previously with propranolol. Hemodynamic studies with propranolol had shown a persistent reduction in cardiac index with total peripheral resistance rising immediately after intravenous therapy', 1' and later returning toward, but not below, pretreatment levels during prolonged oral therapy.9' 10 This study was designed, therefore, to provide an in-depth analysis of the hemodynamic, cardiovascular, reflexive, and metabolic effects of timolol immediately after intravenous administration and with prolonged oral therapy.
Materials and Methods
Thirteen men and three women (mean age 46 years; range 26-61) with mild to moderately severe essential hypertension, who underwent full clinical evaluation to exclude secondary causes of hypertension, are the subjects of this report. Patients with any of the following clinical problems were excluded from this study: sinus bradycardia (less than 52 beats/min); atrioventricular block; malignant hypertension; congestive heart failure; angina pectoris or myocardial infarction in the preceding year; valvular heart disease; bronchospasm of any etiology; diabetes mellitus or spontaneous hypoglycemia; hepatic, renal, hematological, or venous timolol and returned toward, but not below, pretreatment values with oral therapy. Left ventricular ejection rate also fell significantly with intravenous timolol but returned toward pretreatment levels with oral therapy. Plasma renin activity was reduced similarly with both modes of administration and its reduction also did not correlate with the fall in arterial pressure. Plasma volume fell in eight of 13 patients. Reflexive responses to the Valsalva maneuver were considerably modified by both intravenous and oral timolol but responses to 500 upright tilt and handgrip were not. Timolol is an effective oral antihypertensive agent with similar hemodynamic and metabolic effects to propranolol. thyroid diseases. Women of childbearing age also were excluded. All patients provided written informed consent according to a statement approved by our local Human Experimentation Committee.
Clinical Studies
Each patient was followed initially for four weeks after discontinuation of all previous antihypertensive medication (including diuretics). At each weekly visit, heart rate and arterial pressure were obtained in the supine and upright positions. If, at the end of this four-week pretreatment period, supine diastolic pressure was between 95 and 120 mm Hg, the patient was included in the study. This, then, comprised a further four-week treatment period, during which all patients were started with a dose of 10 mg timolol twice daily. The dose was increased at weekly intervals by 10 mg twice-daily increments to a maximum dosage of 30 mg twice daily until diastolic pressure fell below 90 mm Hg or until a diastolic pressure fall of more than 10 mm Hg was achieved. If the heart rate was 52 beats/min or less, the medication was not increased. At the conclusion of this fourweek treatment period, a final two-week period in which the patient received placebo tablets was instituted.
Hemodynamic Evaluation
At the conclusion of the four-week pretreatment period, each patient underwent hemodynamic evaluation by previously described methods." In brief, these studies were performed in the morning after an overnight fast in the unpremedicated state. Small segments of polyethylene tubing were introduced by the Seldinger method into an antecubital vein and brachial artery and advanced to the level of the superior vena cava and shoulder, respectively. Continuous recording of arterial and venous pressures was made simultaneously with the electrocardiogram (lead II). Control supine determinations (in triplicate) of cardiac output were obtained by the indicator (indocyanine green) dyedilution technique. The following hemodynamic indices were calculated: mean arterial pressure, by adding one-third of the pulse pressure to the diastolic pressure; cardiac index, by 140 
Laboratory
Routine hematological and biochemical determinations were obtained before and after intravenous timolol, at the end of the four-week active treatment period, and once more at the end of the placebo period. These investigations included: a complete blood count (with platelet and a differential white cell counts); serum sodium, potassium, chloride, urea, calcium, phosphorus, bilirubin, glucose, glutamic oxaloacetic transferase, and alkaline phosphatase concentrations. Twenty-four-hour urine samples were obtained at each of these stages for estimation of urinary sodium, potassium, creatinine, and aldosterone concentrations.
Chest X-rays and electrocardiograms were also obtained at each stage. Plasma renin activity (ng/ml/hr) also was determined.'3 Blood for these estimations was withdrawn in the supine position at the following times during hemodynamic evaluation: a control sample 30 minutes after stabilization, one hour after intravenous timolol, and after four weeks' therapy after 30-minute supine stabilization.
Results

Clinical Studies
Fifteen of the 16 patients completed this aspect of the study. Supine systolic (P < 0.05) and diastolic (P < 0.01) pressures were reduced by one week of treatment and they continued to remain significantly reduced at week 4 (table  1) . Twelve patients demonstrated a fall in arterial pressure at the end of one week of active treatment and 10 continued to have a reduction in pressure throughout the timolol period. During the final placebo period, arterial pressure returned to pretreatment levels (table 1). A 20% reduction in heart rate was found at the end of one week's therapy; no further fall in heart rate occurred thereafter.
Hemodynamics
A consistent and significant fall in heart rate was found with both intravenous and oral timolol, the fall being more marked with oral therapy ( (table 4) . No correlation was found between pretreatment plasma renin activity and the fall in arterial pressure, or between the fall in plasma renin activity and the fall in arterial pressure. There was no significant change in plasma or urinary sodium and potassium during the study but urinary excretion of aldosterone fell significantly (P < 0.05; table 4). Discussion This study confirms previous reports of the antihypertensive effects of oral timolol both in the supine and upright positions.'' A fall in systolic and/or diastolic pressure of at least 10 mm Hg occurred in ten patients by the end of the active treatment period. In four of the remaining five patients a fall in arterial pressure was observed by the first week's outpatient visit, but this was not sustained. No clinical or biochemical adverse effects of the drug were observed and the medication was well tolerated by all patients.
Our results with regard to the hemodynamic effects of acute (i.v.) and prolonged (oral) administration of timolol were similar to those previously described for propranolol.9 10 Thus, cardiac index fell similarly in both conditions, but arterial pressure remained unaltered following intravenous administration, and it fell only during prolonged oral therapy. Therefore, calculated total peripheral resistance rose significantly with intravenous timolol and then fell toward (but not below) pretreatment levels with oral therapy, suggesting some form of adaptation of the peripheral vasculature to oral timolol.95 Whether this initial increase in total peripheral resistance would not occur with oral therapy is unknown; however, most studies reported with Nonetheless, certain subtle differences exist between these two beta-adrenergic receptor blocking agents in regard to stroke index and left ventricular ejection rate. Stroke index fell similarly following intravenously administered propranolol'6 and timolol, returning to pretreatment levels with propranolol,'0 and above control values (although not significantly so) with timolol. In contrast, left ventricular ejection rate index remained reduced with long-term propranolol therapy despite a fall in arterial pressure.10 With timolol, however, the fall in pressure was accompanied by a return of left ventricular ejection rate index toward pretreatment levels. These data suggest that timolol may have less of a myocardial depressant effect than propranolol, a finding previously noted in experimental animal studies.17
The alterations in plasma volume were similar to those previously described for propranolol.58 Overall, there was no significant change in plasma volume with prolonged timolol therapy, but eight patients did show a fall in intravascular volume, findings similar to those with propranolol treatment. These findings re-emphasize that the beta-receptor blocking drugs appear to be the only antihypertensive agents (apart from diuretics) which do not expand plasma volume as arterial pressure falls. These data are of particular interest when considered in relation to the induced changes in peripheral plasma renin activity. Despite the presence of three stimuli to renin release (i.e., fall in cardiac output, fall in arterial pressure, and contraction of plasma volume), '9 plasma renin activity remained significantly reduced during therapy. This suggests that timolol prevented the expected renin release from the kidney in response to these stimuli, most likely through inhibition of the renal beta receptors. The lack of correlation between fall in plasma renin activity and fall in arterial pressure, and the fact that plasma renin activity fell during intravenous timolol administration (when pressure remained unchanged), strongly suggest that reduced generation of angiotensin II was not the mechanism through which arterial pressure was lowered following beta receptor inhibition. Indeed, these sequential findings were observed previously with timolol20 as well as with other beta blocking agents.2' 23 The fall in urinary aldosterone excretion therefore seems to be due to suppression of plasma renin activity, thereby reducing the angiotensin II-mediated aldosterone release.
The modification of cardiovascular responses with the Valsalva maneuver was a feature of both intravenous and oral timolol, and was of a similar magnitude by both routes of administration. Since arterial pressure fell with only oral therapy, these quantitative changes most likely also resulted from beta-receptor inhibition rather than from reduction in arterial pressure. This modification of the Valsalva responses has been demonstrated previously with both cardioselective and noncardioselective beta-blockers.21 A "square wave" Valsalva response was noted in two patients after administration of intravenous timolol. This was not considered to result from cardiac failure since neither of the patients was symptomatic or had other evidence of failure. Infusion of L-norepinephrine has produced a square wave response in normal subjects.25 One possible explanation for this phenomenon in our two patients might be through overriding alpha-receptor activity which was postulated to be the mechanism with norepinephrine infusion.24 One of these patients had repeat hemodynamic evaluation during oral timolol therapy, but on this occasion no square wave Valsalva response was observed. Therefore, still other factors (including variability of Valsalva maneuver responses) may explain the phenomenon. Timolol did not induce any significant clinical or physiological disturbances during upright tilt (including postural hypotension); and no major reflexive alterations were observed with isometric (handgrip) exercise.
In conclusion, timolol seems to be an effective antihypertensive agent in man and was well tolerated. Its hemodynamic actions are similar to propranolol, causing a fall in arterial pressure, accompanied by a sustained reduction in cardiac output (and heart rate) only with prolonged oral therapy. However, left ventricular ejection rate remained depressed with only propranolol. Both agents inhibit renin release from the kidney, and both had similar effects in failing to expand plasma volume with prolonged treatment in patients with mild to moderately severe hypertension. The latter observation may be related to the associated reduction in aldosterone excretion. cessation of infusion. In contrast, when the drug was administered intra-arterially to the iliac bed, arterial pressure did not fall and only iliac vasodilation was observed. Peak cardiac effects were characterized by increases in heart rate and LV dP/dt, along with marked reductions in LV end-systolic diameter (-13 ± 2%), and in end-diastolic diameter (-17 ± 2%) and pressure. LV end-diastolic diameter fell even when heart rate was maintained at a constant rate by pacing.
Thus, in the conscious dog, NP reduced LV dimensions substantially, while inducing changes in peripheral beds. The differences in these effects depend on interactions between the direct effects of NP and the opposing effects of reflex adjustments which appear sufficiently powerful to result in net constriction of the iliac bed late during the infusion.
limitations dictated by the use of human subjects, or in anesthetized animal preparations where the complicating effects of anesthesia and recent surgery are present.', 1 ' The goal of the present study was to characterize more completely the hemodynamic effects of intravenously administered NP in the normal conscious dog. Hemodynamic measurements were obtained instantaneously and continuously before, during, and after the intravenous infusion of this drug in order to study the 
